Pfizer repels Covid-19 sales tumble to raise 2026 guidance

EarningsEliquisPositive

AI Analysis

Summary

Pfizer raised its 2026 guidance, offsetting Covid-19 sales declines through strong performance of blockbuster drugs like Eliquis, demonstrating its revenue diversification beyond pandemic products.

Financial Highlights

Guidance

raised for 2026

Importance:5/10

Sentiment:

0.60

guidance raiserevenue recoveryblockbuster drugspost-COVID

Related Companies

$PFE

Read the original article

Published by Pharmaceutical Technology on August 4, 2026 3:29 PM

Read Original